AlphAIAlphAI — Financial news for AI agents
zacks.comAUG 202 min read$AUPH

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

Original reporting
zacks.com
Published Aug 20, 2026, 3:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises — source image
Source · zacks.com
Decision brief

The 30-second read

$AUPHBullishMed
01

Why it matters

The settlement secures Aurinia's revenue stream while limiting Teva's generic launch, influencing both stocks.

02

Market read

The legal settlement directly impacts Aurinia's exclusivity period and stock price, while constraining Teva's generic entry.

03

What to watch

Potential regulatory delays for the generic could further affect Teva's timeline.

Relevance 7/10Novelty 7/10Timing: post‑settlement price rise

Background

Aurinia's Lupkynis is the first FDA‑approved oral therapy for lupus nephritis, generating $153 M in sales in H1 2026.

Company-level read

Ticker impact

$AUPHBullishHigh confidence
Context

Aurinia settled its voclosporin patent lawsuit with Teva, delaying generic entry until Dec 2036 and causing a 6% stock rise.

Expected impact

Potential upside of 5‑8% over the next 3‑6 months if no further challenges arise.

Evidence & confidence

Extended exclusivity reduces competitive pressure and aligns with recent sales growth.

$TEVABearishMedium confidence
Context

Teva agreed to the settlement, accepting a launch delay for its generic voclosporin until Dec 2036.

Expected impact

Possible short‑term downside of 2‑4% as launch timeline is pushed back.

Evidence & confidence

Delayed entry reduces immediate market opportunity for the generic product.

Market effects

Sector

Biotech sector may see reduced generic pressure on lupus therapies.

Regional

U.S. biotech investors could favor Aurinia over peers.

Global

Limited to companies with similar autoimmune drug pipelines.

Counterpoint

What could challenge this read

If Teva successfully challenges the patents later, Aurinia's exclusivity could be shortened.

Key entities

  • Company
    Aurinia Pharmaceuticals

    Biotech firm with Lupkynis for lupus nephritis.

  • Company
    Teva Pharmaceuticals

    Generic drug manufacturer seeking to launch voclosporin.

Read at source← All news

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 13
$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

medicaldialogues.in2 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

zacks.com6 min